

Form PTO-1449 (modified) JUL 30 2002  
 PATENTS & TRADEMARKS OFFICE  
 List of Patents and Publications for Applicant's  
 INFORMATION DISCLOSURE STATEMENT  
 (Use several sheets if necessary)

Atty. Docket No. Serial No.  
 UTSC:664US 09/599,152

Applicant  
 David Yang *et al.*

Filing Date:  
 June 21, 2000

Group:  
 1616

RECEIVED  
 AUG 01 2002  
 TECH CENTER 1600/2900

U.S. Patent Documents  
*See Page 1*

Foreign Patent Documents  
*See Page 1*

Other Art  
*See Page 2*

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
R	A1	5,108,921	04/28/92	Low <i>et al.</i>	435	240.1	03/28/90
T	A2	5,279,811	1/18/94	Bergstein <i>et al.</i>	424	1.1	1/26/88
T	A3	5,416,016	05/16/95	Low <i>et al.</i>	435	240.1	03/13/92
T	A4	5,635,382	06/03/97	Low <i>et al.</i>	435	172.3	12/05/94
T	A5	5,688,488	11/18/97	Low <i>et al.</i>	424	1.69	05/16/95
T	A6	5,730,968	3/24/98	Butterfield <i>et al.</i>	424	78.37	3/31/94
T	A7	5,820,847	10/13/98	Low <i>et al.</i>	424	9.1	01/15/97
T	A8	5,951,964	9/14/99	Dean <i>et al.</i>	424	1.69	6/4/93
T	A9	5,955,053	9/21/99	Marzilli <i>et al.</i>	424	1.11	5/6/96
T	A10	5,977,163	11/2/99	Li <i>et al.</i>	514	449	3/11/97
T	A11	5,986,074	11/16/99	Marzilli <i>et al.</i>	534	14	12/18/97
X	A12	6,197,278	3/6/01	Blankenberg <i>et al.</i>	424	1.69	4/29/98

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
W	C37	Alper <i>et al.</i> , "Assessment of renal functional changes following transurethral prostatectomy using tc-99m ethylenedicycysteine," <i>J. Nuclear Med.</i> , 37:289P, Abstract No. 1292, 1996.
T	C38	Anderson <i>et al.</i> , "N,N'-ethylene-di-L-cysteine (ec) complexes of ga(III) and In (III): molecular modeling, thermodynamic stability and in vivo studies," <i>Nucl. Med. Biol.</i> , 22:165-173, 1995.

Examiner:

DATE CONSIDERED:

10/25/02

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

JUL 3 0 2002

Atty. Docket No.

UTSC:664US

Serial No.

09/599,152

## List of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
June 21, 2000Group:  
1616RECEIVED  
AUG 01 2002  
TECH CENTER 1600/2900

## U.S. Patent Documents

See Page 1

## Foreign Patent Documents

See Page 1

## Other Art

See Page 2

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
70	C39	Baidoo and Lever, "Evaluation of a diaminedithiol-based bifunctional chelate for labeling small molecules with <sup>99m</sup> Tc," <i>Techneitum and Rhenium in Chemistry and Nuclear Medicine</i> , 1990.
	C40	Baidoo <i>et al.</i> , "Synthesis of a new diaminedithiol bifunctional chelate for the preparation of neutral technetium complexes," <i>J. Nuclear Med.</i> , 31:806, Abstract No. 414, 1990.
	C41	Bar-Sever <i>et al.</i> , "Comparison of living related donor and recipient renograms in predicting the early posttransplantation course," <i>J. Nuclear Med.</i> , 37:292P, Abstract No. 1305, 1996.
	C42	Bush <i>et al.</i> , "Definitive evidence for hypoxic cells influencing cure in cancer therapy," <i>Br J Cancer</i> , (Suppl. III) 37:302-306, 1978.
	C43	Campbell <i>et al.</i> , "Folate-binding protein is a marker for ovarian cancer," <i>Cancer Res</i> , 51:5329-5338, 1991.
	C44	Chen <i>et al.</i> , "Biological and pharmacokinetic evaluation of tc-99m ma2g2-b: a potential renal agent," <i>J. Nuclear Med.</i> , 35:263P, Abstract No. 1082, 1994.
	C45	Cherif <i>et al.</i> , "Rapid synthesis of [ <sup>18</sup> F]Fluoro-1-(2'-Nitro-1'-Imidazolyl)-2-Propanol ([ <sup>18</sup> F]Fluoromisonidazole)," <i>Pharm Res.</i> , 11:466-469, 1994.
	C46	Cleynhens <i>et al.</i> , "Synthesis and biological evaluation in mice of a monoamide derivative of tc-99m-l,l-ec," <i>J. Nuclear Med.</i> , 38:186P, Abstract No. 799, 1997.
	C47	Coney <i>et al.</i> , "Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing," <i>Cancer Res</i> , 54:2448-2455, 1994.
	C48	Corlja <i>et al.</i> , "Contribution of radiolytically induced dissociation of 99mtc-d,l-hmpao in aqueous solutions," <i>J. Nuclear Med.</i> , 31:806, Abstract No. 413, 1990.
	C49	Craig <i>et al.</i> , "Renal outcomes for children one year after urinary tract infection," <i>J. Nuclear Med.</i> , 37:46P, Abstract No. 175, 1996.
70	C50	Dagli <i>et al.</i> , "Analysis of the complete dynamic scan data for camera-based determination of renal function," <i>J. Nuclear Med.</i> , 37:91P, Abstract No. 354, 1996.
70	C51	de Klerk <i>et al.</i> , "Aspirin versus captopril renography in the diagnosis of renal artery stenosis," <i>J. Nuclear Med.</i> , 37:289P, Abstract No. 1291, 1996.

Examiner


EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

DATE CONSIDERED:

10/25/02

Form PTO-1449 (modified)

JUL 3 0 2002

List of Patents and Publications  
FILING DATE  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

UTSC:664US

Serial No.

09/599,152

Applicant

David Yang *et al.*

Filing Date:

June 21, 2000

Group:

1616

RECEIVED

AUG 01 2002

TECH CENTER 1600/2900

## U.S. Patent Documents

See Page 1

## Foreign Patent Documents

See Page 1

## Other Art

See Page 2

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
<i>DJ</i>	C52	Dewanjee <i>et al.</i> , "Labeling antisense oligodeoxynucleotide (on) with tc-99m and hybridization with c-myc oncogene mrna in p388 leukemic cells," <i>J. Nuclear Med.</i> , 35:263P, Abstract No. 1081, 1994.
<i>1</i>	C53	Dezutter <i>et al.</i> , "Preparation and biological evaluation of technetium- <sup>99m</sup> -L,L-propylenedicysteine" <i>J. of Labelled Cpd. Radiopharm.</i> , 42:553-565, 1999.
	C54	Dische, "A review of hypoxic-cell radiosensitization," <i>Int J Radiat Oncol Biol Phys</i> , 20:147-152, 1991.
	C55	Eisenhut <i>et al.</i> , "Synthesis and <i>In Vivo</i> Testing of a bromobutyl substituted 1,2-Dithia-5,9-diazacycloundecane: a versatile precursor for new <sup>99m</sup> Tc-bis(aminoethanethiol) complexes," <i>Nucl. Med. Biol.</i> , 16:805-811, 1989.
	C56	Eshima <i>et al.</i> , "Evaluating the role of protein binding on the renal extraction of tc-99m tubular agents utilizing an isolated perfused rat kidney model," <i>J. Nuclear Med.</i> , 37:47P, Abstract No. 178, 1996.
	C57	Fanciulli <i>et al.</i> , "Glycolysis and growth rate in normal and in hexokinase-transfected NIH-3T3 cells," <i>Oncology Res.</i> , 6:405-409, 1994.
	C58	Franklin <i>et al.</i> , "New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma," <i>Int J Cancer-Supplement</i> , 8:89-95, 1994.
	C59	Giraud <i>et al.</i> , "Application to a cartilage targeting strategy: Synthesis and in vivo biodistribution of <sup>14</sup> C-labelled quaternary ammonium-glucosamine conjugates," <i>Bioconjug. Chem.</i> , 11:212-218, 2000.
	C60	Goh <i>et al.</i> , "Growth hormone promotion of tubulin polymerization stabilizes the microtubule network and protects against colchicine-induced apoptosis," <i>Endocrinology</i> , 139:4364-4372, 1998.
<i>DJ</i>	C61	Guozheng and Boli, "A new potential renal imaging agent 99mtcn-ec," <i>J. Labelled compounds and Radiopharmaceuticals</i> , XXXVII:797-798, 1995.
<i>DJ</i>	C62	Harada <i>et al.</i> , "Insulin-induced egr-1 expression in chinese hamster ovary cells in insulin receptor and insulin receptor substrate-1 phosphorylation-independent," <i>J. Biol Chem.</i> , 270:26632-26638, 1995.

Examiner: *P. O'Neil*DATE CONSIDERED: *10/25/02*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

JUL 3 0 2002

List of Patents and Publications for Amendment's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.  
UTSC:664USSerial No.  
09/599,152Applicant  
David Yang *et al.*Filing Date:  
June 21, 2000Group:  
1616

AUG 01 2002

RECEIVED  
TECH CENTER 1600/2900

## U.S. Patent Documents

See Page 1

## Foreign Patent Documents

See Page 1

## Other Art

See Page 2

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
PDG	C63	Hay <i>et al.</i> , "Hypoxia-selective antitumor agents. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitizers," <i>J Med. Chem.</i> , 37:381-391, 1994.
	C64	Hermann and Patel, "Adaptive recognition by nucleic acid aptamers," <i>Science</i> , 287:820-825, 2000.
	C65	Holm <i>et al.</i> , "Folate receptor of human mammary adenocarcinoma," <i>APMIS</i> , 102:413-419, 1994.
	C66	Hsueh and Dolnick, "Altered folate-binding protein mRNA stability in KB cells grown in folate-deficient medium," <i>Biochem Pharmacol</i> , 45:2537-2545, 1993.
	C67	Ilgan <i>et al.</i> , " <sup>99m</sup> Tc-ethylenedicysteine-folate: a new tumor imaging agent, synthesis, labeling and evaluation in animals," <i>Cancer Biotherapy &amp; Radiopharmaceuticals</i> , 13:427-435, 1998.
	C68	Itoh <i>et al.</i> , "Graphic (patlak) method in tc-99m-mag3 renal scintigraphy: noninvasive calculation of extraction fraction (ef) and renal plasma flow (RPF)," <i>J. Nuclear Med.</i> , 37:291P, Abstract No. 1300, 1996.
	C69	John <i>et al.</i> , "Tc-99m labeled ethylenediamines: quest for sigma receptor chelates," <i>J. Nuclear Med.</i> , 38:186P, Abstract No. 798, 1997.
	C70	Jones and Mayer, "Glucose metabolism in the rat small intestine: the effect of glucose analogues on hexokinase activity," <i>Biochem. J.</i> , 132:125-128, 1973.
	C71	Kabasakal <i>et al.</i> , "Clinical comparison of technetium- <sup>99m</sup> -ec, technetium- <sup>99m</sup> -MAG3 and iodine-131-OIH in renal disorders," <i>J. Nucl. Med.</i> , 36(2):224-228, 1995.
	C72	Kabasakal <i>et al.</i> , "Evaluation of technetium-99m-ethylenedicysteine in renal disorders and determination of extraction ratio," <i>J. Nucl. Med.</i> , 36(8):1398-1403, 1995.
	C73	Kabasakal <i>et al.</i> , "Prospective validation of single plasma sample <sup>99m</sup> Tc-ethylenedicysteine clearance in adults," <i>J. Nucl. Med.</i> , 40:429-431, 1999.
	C74	Kabasakal <i>et al.</i> , "Simplified technetium- <sup>99m</sup> -EC clearance in adults from a single plasma sample, <i>J. Nuclear Med.</i> , 38:1784-1786, 1997.
	C75	Kanvinde <i>et al.</i> , "Technetium-99m-γ-pyrone: a new class of tc-99m cationic complexes," <i>J. Nuclear Medicine</i> , 31:908, Abstract, 1990.

Examiner:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

DATE CONSIDERED:

Form PTO-1449 (modified) JUL 30 2002  
 PATENTS TRADEMARKS  
 INFORMATION DISCLOSURE STATEMENT  
 (Use several sheets if necessary)

Atty. Docket No. UTSC:664US	Serial No. 09/599,152
Applicant David Yang <i>et al.</i>	
Filing Date: June 21, 2000	Group: 1616

RECEIVED

AUG 01 2002

TECH CENTER 1600/2900

U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 2</i>
--	---	--------------------------------

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>DJ</i>	C76	Kao <i>et al.</i> , "Role of radioisotope penile plethysmigraphy in the evaluation of penile hemodynamic of impotent patients," <i>J. Nuclear Med.</i> , 37:292P, Abstract No. 1304, 1996.
	C77	Kengen, "Good results of tc-99m-mag3 clearance measurements with a dual headed gamma camera without plasma sampler," <i>J. Nuclear Med.</i> , 37:91P, Abstract No. 353, 1996.
	C78	Kikukawa <i>et al.</i> , "Early and delayed Tc-99m ECD brain SPECT in SLE patients with CNS involvement," <i>Ann Nucl Med.</i> 14:25-32, 2000.
	C79	Kim <i>et al.</i> , "Synthesis, biodistribution and imaging of mammary tumors using 99mtc-ec-polyglutamate; a glutamate receptor peptide," <i>J. Nuclear Medicine</i> , 41:231P Abstract, 2000.
	C80	Kranz <i>et al.</i> , "Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis," <i>Proc Natl Acad Sci</i> , 92:9057-9061, 1995.
	C81	Lamberts <i>et al.</i> , "Somatostatin receptor imaging in vivo localization of tumors with a radiolabeled somatostatin analog," <i>J. Steroid Biochem Mol Biol</i> , 37:1079-1082, 1990.
	C82	Leamon and Low, "Cytotoxicity of momordin-folate conjugates in cultured human cells," <i>J Biol Chem</i> , 267:24966-24971, 1992.
	C83	Leamon <i>et al.</i> , "Cytotoxicity of folate-pseudomonas exotoxin conjugates toward tumor cells," <i>J Biol Chem</i> , 268:24847-24854, 1993.
	C84	Lee and Low, "Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis," <i>J Biol Chem</i> , 269:3198-3204, 1994.
	C85	Liang <i>et al.</i> , "The use of diaminodithiol for labeling small molecules with technetium-99m," <i>Nucl. Med. Biol.</i> , 14:63-67, 1987.
	C86	Lu, "Antimitotic agents," In: Foye, W.O. Ed., "Cancer chemotherapeutic agents," Washington, DC: American Chemical Society, 345-368, 1995.
<i>DJ</i>	C87	Mang'era and Verbruggen, "Synthesis and evaluation of beta-homocysteine derivatives of 99mtc-l,l-ec and 99mtc-l,l-ecd," <i>J. of Labelled Compounds and Radiopharmaceuticals</i> , 42:683-699, 1999.
<i>DJ</i>	C88	Mason <i>et al.</i> , "99mtc-desferoxamine: production, stability and solute clearance measurements after aerosolization," <i>J. Nuclear Med.</i> , 31:908, Abstract No. 865, 1990.

Examiner:

*D. Jones*


DATE CONSIDERED:

*10/25/02*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

JUL 3 0 2002



List of Patents and Publications FOR APPRAISEMENT'S

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

UTSC:664US

Serial No.

09/599,152

Applicant

David Yang *et al.*

RECEIVED

AUG 01 2002

TECH CENTER 1600/2900

Filing Date:

June 21, 2000

Group:

1616

## U.S. Patent Documents

See Page 1

## Foreign Patent Documents

See Page 1

## Other Art

See Page 2

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
P	C89	Mather <i>et al.</i> , "Tumour cell uptake of technetium dithiocarbamate complexes," <i>J. Nuclear Med.</i> , 38:186P, Abstract No. 797, 1997.
	C90	Mease <i>et al.</i> , "Comparison of renal agents for detecting unilateral acute ischemic/reperfusion renal injury in rats," <i>J. Nuclear Med.</i> , 36:231P, Abstract No. 1033, 1995.
	C91	Michiels <i>et al.</i> , "Simultaneous estimation of effective renal plasma flow and glomerular filtration rate using tc-99m-ec," <i>J. Nuclear Med.</i> , 37:91P, Abstract No. 355, 1996.
	C92	Mochizuki <i>et al.</i> , "Synthesis of poly-L-glutamates containing 5-substituted uracil moieties," <i>Nucleic Acids Symp. Ser.</i> , 16:121-124, 1985.
	C93	Moller <i>et al.</i> , "Biologic activities of naturally occurring human insulin receptor mutations," <i>J. Biol. Chem.</i> , 266:10995-11001, 1991.
	C94	Moran, "Technetium- <sup>99m</sup> -EC and other potential new agents in renal nuclear medicine," <i>Seminars in Nucl. Med.</i> , 29: 91-101, 1999.
	C95	Morton <i>et al.</i> , "Comparison of 2-point postural drainage with diuresis renography in the assessment hydronephrosis," <i>J. Nuclear Med.</i> , 37:46P, Abstract No. 174, 1996.
	C96	Mrhac <i>et al.</i> , "Abnormal first-pass flow through the azygos vein from valsalva maneuver," <i>Clinical Nucl. Med.</i> , 21:331-332, 1996.
	C97	Nosco <i>et al.</i> , "Development of a kit formulation for 99mTc-MAG3 of very high purity and very high stability," <i>J. Nuclear Med.</i> , 31:908, Abstract No. 863, 1990.
	C98	Offield <i>et al.</i> , "PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum," <i>Development</i> , 122:983-995, 1996.
	C99	Orr <i>et al.</i> , "Similarity of folate receptor expression in UMSCC 38 cells to squamous cell carcinoma differentiation markers," <i>J Natl Cancer Inst</i> , 87:299-303, 1995.
V	C100	Ozker <i>et al.</i> , "Technetium- <sup>99m</sup> -N,N-ethylenedicycysteine-a comparative study of renal scintigraphy with technetium- <sup>99m</sup> -MAG3 and iodine-131-OIH in patients with obstructive renal disease," <i>J. Nucl. Med.</i> , 35:840-845, 1994.
P A	C101	Piper <i>et al.</i> , "A synthetic approach to poly( $\gamma$ -glutamyl) conjugates of methotrexate," <i>J. Med. Chem.</i> , 26:291-294, 1983.

Examiner:

*Dennis*

DATE CONSIDERED:

*0/25/02*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified JUL 3 0 2002)



List of Patents and Publications for Applicant's  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.  
UTSC:664USSerial No.  
09/599,152Applicant  
David Yang *et al.*Filing Date:  
June 21, 2000Group:  
1616

RECEIVED

AUG 01 2002

U.S. Patent Documents  
*See Page 1*Foreign Patent Documents  
*See Page 1*Other Art  
*See Page 2***Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**


Exam. Init.	Ref. Des.	Citation
<i>DJ</i>	C102	Pirnettis <i>et al.</i> , "Synthesis and characterization of the tcd(ec) complex, a renal imaging agent," <i>J. Nuclear Med.</i> , 35:263P, Abstract No. 1079, 1994.
	C103	Popovici <i>et al.</i> , "The influence of some antibiotics on hexokinase and pyruvate-kinase activity in the rat liver and kidney," <i>Arch. int. Pharmacodyn.</i> , 193:80-86, 1971.
	C104	Prvulovich <i>et al.</i> , "Clinical evaluation of technetium- <sup>99m</sup> -L,L-ethylenedicysteine in patients with chronic renal failure," <i>J. Nucl. Med.</i> , 38:809-814, 1997.
	C105	Raffauff <i>et al.</i> , "Colchicine. Derivatives of trimethylcolchicinic acid," <i>J. Am Chem Soc.</i> , 75:5292-5294, 1953.
	C106	Ratner and Clarke, "The action of formaldehyde upon cysteine," <i>J. Am Chem. Soc.</i> , 59:200-206, 1937.
	C107	Rogers <i>et al.</i> , "Neomycin effects on glucose transport by rat small intestine," <i>Digestion</i> , 1:159-164, 1968.
	C108	Ross <i>et al.</i> , "Differential regulation of folate receptor isoforms in normal and malignant tissue in vivo and in established cell lines," <i>Cancer</i> , 73:2432-2443, 1994.
	C109	Sasaki <i>et al.</i> , "Assessment of antioxidative ability in brain: imaging of glutathione localization with technetium-99m meso-hexamethyl propyleneamine," <i>J. Nuclear Med.</i> , 35:263P, Abstract No. 1083, 1994.
	C110	Sato <i>et al.</i> , "Simple estimation of fractional renal uptake of tc-99m mag3 using graphical analysis without syringe counting and renal depth correction," <i>J. Nuclear Med.</i> , 37:292P, Abstract No. 1303, 1996.
	C111	Shankar <i>et al.</i> , "Glucosamine infusion in rats mimics the beta-cell dysfunction of non-insulin-dependent diabetes mellitus," <i>Metabolism</i> , 47:573-577, 1998.
<i>DJ</i>	C112	Shattuck <i>et al.</i> , "Validation of the two sample technique for measuring gfr in renal transplant patients," <i>J. Nuclear Med.</i> , 36:231P, Abstract No. 1036, 1995.
<i>DJ</i>	C113	Shuke <i>et al.</i> , "Modified renal counting method for estimation of tc-99m mag3 renal clearance," <i>J. Nuclear Med.</i> , 37:291P, Abstract No. 1301, 1996.

Examiner:

DATE CONSIDERED:

10/25/02

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MP&amp;P609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)

**List of Patents and Publications for Applicant's  
INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Atty. Docket No.  
UTSC:664USSerial No.  
09/599,152Applicant  
David Yang *et al.*Filing Date:  
June 21, 2000Group:  
1616RECEIVED  
AUG 01 2002  
TECH CENTER 1600/2900U.S. Patent Documents  
*See Page 1*Foreign Patent Documents  
*See Page 1*Other Art  
*See Page 2***Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
<i>ad</i>	C114	Stoffel <i>et al.</i> , "Evaluation of technetium-99m-L,L-ec in renal transplant recipients: a comparative study with technetium- <sup>99m</sup> -MAG3 and iodine-125-OIH, <i>J. Nucl. Med.</i> , 35:1951-1958, 1994.
<i>ad</i>	C115	Subramanian <i>et al.</i> , "Transchelation reactions in labeling ecd with tc-99m," <i>J. Nuclear Med.</i> , 31:908, Abstract No. 867, 1990.
	C116	Suzuki <i>et al.</i> , "A modified graphic method for estimation of glomerular filtration index using dynamic renal images with tc-99m dtpa," <i>J. Nuclear Med.</i> , 36:231P, Abstract No. 1035, 1995.
	C117	Tait and Smith, "Site-specific mutagenesis of annexin V: role of residues from Arg-200 to Lys-207 in phospholipid binding," <i>Arch Biochem Biophys</i> , 288:141-144, 1991.
	C118	Taylor <i>et al.</i> , "Comparison of tc-99m0(n,n1-ethylenedicycysteine isomers in rats and in normal volunteers," <i>J. Nuclear Med.</i> , 37:46P-47P, Abstract No. 177, 1996.
	C119	Taylor <i>et al.</i> , "Comparison of technetium- <sup>99m</sup> -LL-EC isomers in rats and humans," <i>J. Nucl. Med.</i> , 38:821-826, 1997.
	C120	Tsukamoto <i>et al.</i> , "The quantitation of absolute tc-99m-dmsa renal uptake in children from planar posterior-view method," <i>J. Nuclear Med.</i> , 37:291P, Abstract No. 1299, 1996.
	C121	Tuli <i>et al.</i> , "Comparison of a simplified quantitation of tc-99m mag-3 renogram to core needle biopsy in the diagnosis of renal transplant rejection," <i>J. Nuclear Med.</i> , 37:289P, Abstract No. 1290, 1996.
	C122	Ugar <i>et al.</i> , "The diagnosis of renovascular hypertension with technetium-99m-ethylenedicycysteine captopril scintigraphy," <i>Investigative Radiology</i> , 31:497-501, 1996.
	C123	Ugar <i>et al.</i> , "Renovascular hypertension due to takayasu's arteritis demonstrated by Tc- <sup>99m</sup> ethylenedicycysteine captopril scintigraphy," <i>Clinical Nuclear Medicine</i> , 21:714-716, 1996.
<i>ad</i>	C124	Ugar <i>et al.</i> , "Technetium- <sup>99m</sup> -ethylenedicycysteine in the diagnosis and follow-up of renovascular hypertension," <i>Investigative Radiology</i> , 31:378-381, 1996.
<i>ad</i>	C125	Ugar <i>et al.</i> , "Technetium- <sup>99m</sup> -ethylenedicycysteine: an alternative agent to detect renovascular hypertension," <i>J. of Nuclear Med.</i> , 38:1662-1664, 1997.
<i>ad</i>	C126	Ugar <i>et al.</i> , "The diagnosis of renovascular hypertension with tc-99m ethylenedicycysteine captopril scintigraphy," <i>J. Nuclear Med.</i> , 37:291P, Abstract No. 1302, 1996.

Examiner:

*[Signature]* DATE CONSIDERED: *10/28/02*  
 EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified) JUL 30 2002 List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Atty. Docket No. UTSC:664US	Serial No. 09/599,152
		Applicant David Yang <i>et al.</i>	RECEIVED AUG 01 2002 TECH CENTER 1600/2900
		Filing Date: June 21, 2000	Group: 1616
U.S. Patent Documents <i>See Page 1</i>		Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 2</i>

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
WJ	C127	Van Nerom <i>et al.</i> , "Comparison of renal excretion characteristics of isomers l,l and d,d of tc-99m ethylenedicycysteine," <i>J. Nuclear Med.</i> , 31:806, Abstract No. 412, 1990.
	C128	Van Nerom <i>et al.</i> , "Optimization of the labelling of ethylenedicycysteine (ec) with technetium-99m," <i>J. Labelled Compounds and Radiopharmaceuticals</i> , XXX:37-39, 1991.
	C129	Van Schepdael <i>et al.</i> , "Capillary electrophoretic analysis of ethylene dicysteine, a precursor of the radiopharmaceutical <sup>99m</sup> Tc ethylene dicysteine," <i>J. Chromatography B</i> , 697:251-254, 1997.
	C130	Verbruggen <i>et al.</i> , "Is syn or anti orientation of the oxotechnetium and carboxyl group in tc-99m renal function agents affecting the renal excretion rate?" <i>J. Labelled Compounds and Radiopharmaceuticals</i> , XXX:86-88, 1991.
	C131	Verbruggen <i>et al.</i> , "Tc-99m l,l-ethylenedicycysteine, a potential alternative to tc-99m mag3," <i>J. Nuclear Med.</i> , 31:908, Abstract No. 864, 1990.
	C132	Villevalois-Cam <i>et al.</i> , "Insulin-induced redistribution of the insulin-like growth factor II/mannose 6-phosphate receptor in intact rat liver," <i>J. Cell. Biochem.</i> , 77:310-322, 2000.
	C133	Washburn <i>et al.</i> , "Reliable kit preparation of tc99m pentavalent dimercaptosuccinic acid [tc-99m (v) dmsa]," <i>J. Nuclear Med.</i> , 35:263P, Abstract No. 1080, 1994.
	C134	Weitman <i>et al.</i> , "Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis," <i>Cancer Res.</i> , 52:6708-6711, 1992b.
	C135	Weitman <i>et al.</i> , "The folate receptor in central nervous system malignancies of childhood," <i>J Neuro-Oncology</i> , 21:107-112, 1994.
	C136	Weitman <i>et al.</i> , "Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues," <i>Cancer Research</i> , 52:3396-3401, 1992.
	C137	Westerhof <i>et al.</i> , "Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: Role of carrier- and receptor-mediated transport systems," <i>Cancer Res.</i> , 51:5507-5513, 1991.
VJ	C138	Yang <i>et al.</i> , "99mtc-ec-deoxyglucose: synthesis, cellular uptake, biodistribution and scintigraphic imaging," <i>J. Labelled Cpd. Radiopharm.</i> , 44:S513-S514, Abstract, 2001.
DJ	C139	Yang <i>et al.</i> , "Imaging tumor folate receptors using 99mtc-ethylenedicycysteine-folate," <i>Proceedings of the American Association for Cancer Research</i> , 40:259, Abstract #1720, 1999.

Examiner:

*[Signature]*

DATE CONSIDERED:

*10/25/02*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

JUL 30 2002

## List of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.  
UTSC:664USSerial No.  
09/599,152Applicant  
David Yang *et al.*Filing Date:  
June 21, 2000Group:  
1616

RECEIVED

AUG 01 2002

TECH CENTER 1600/2900

U.S. Patent Documents  
*See Page 1*Foreign Patent Documents  
*See Page 1*Other Art  
*See Page 2***Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
<i>R</i>	C140	Yang <i>et al.</i> , "Imaging tumor folate receptors using radiolabeled folate and methotrexate," <i>J. Labelled Cpd. Radiopharm.</i> , 42:S696-S697, 1999.
<i>T</i>	C141	Yang <i>et al.</i> , "Molecular imaging using 99m-tc-ec-nitroimidazole, and 99mtc-ec-annexin v in tumor-bearing rodents," <i>Proceedings fo the American Association for Cancer Research Annual Meeting</i> , 41:766, Abstract, 2000.
	C142	Yang <i>et al.</i> , "Noninvasive assessment of tumor hypoxia with <sup>99m</sup> Tc labeled metronidazole," <i>Pharmaceutical Research</i> , 15:743-750, 1999.
	C143	Yoshino <i>et al.</i> , "Differential effects of troglitazone and D-chiroinositol on glucosamine-induced insulin resistance in vivo in rats," <i>Metabolism</i> . 48:1418-23, 1999.
<i>Z</i>	C144	Zakko <i>et al.</i> , "Biliary excretion of Tc- <sup>99m</sup> ec in renal studies," <i>Clinical Nuclear Medicine</i> , 23:417-419, 1998.
<i>D</i>	C145	Zarenayrizi <i>et al.</i> , "Synthesis of [ <sup>99m</sup> Tc] ethylenedicycysteine-colchicine for evaluation of antiangiogenic effect," <i>Anti-Cancer Drugs</i> , 10:685-692, 1999.

Examiner:

*R. Jones*

DATE CONSIDERED:

*1/25/03*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.